The US contract development and manufacturing organization (CDMO) Agno Pharma has taken over compatriot firm Lubrizol Particle Sciences to increase its drug product formulation offerings.
Astellas’ drug fezolinetant (Veoza) has been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the prevention of hot flashes during the menopause.
The oral treatment belzutifan, developed by MSD (known as Merck in the US) and branded as Welireg, has received the green light from the US Food and Drug Administration (FDA) for the treatment of an advanced form of renal cell carcinoma (RCC).
A lead candidate psychedelic drug developed by the US company MindMed has shown the potential to treat generalized anxiety disorder in a phase 2b trial.
Mission Therapeutics, a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to proceed with a phase 2 trial for its kidney...
The AIDS and Cancer Specimen (ACSR), a biorepository of specimens collected from persons living with HIV (PLWH) has today (December 12) announced it is using software from Proscia that can provide near real-time access to pathology data to investigators...
Clinical-stage pharma company, PharmaKure which develops precision medicine for Alzheimer’s Disease and other neurological diseases has announced a collaboration agreement with one of the largest comprehensive universities in Malaysia.
Dr. Michael O’Neal, chief medical officer at Clario, believes that many drugs ultimately fail due to common operational and data challenges that could, and should, be corrected.
OSP had a great conversation with Mike Connell, chief operating officer, at Enthought. The discussion centered around aritificial intelligence (AI) which have been the buzzwords in pharma and a number of other industries for at least the last year.
Merck has entered into a $70 million licensing agreement with Abbisko Therapeutics for pimicotinib, which is currently being evaluated in a phase 3 study for the treatment of tenosynovial giant cell tumor (TGCT).
Outsourcing Pharma is delighted to invite you to join our not-to-be-missed webinar on one of the most important areas of the industry – patient centricity – and its solutions.
Volunteers with conditions including depression, alcohol use disorder, and anorexia are being sought by Clerkenwell Health, to join its seminal clinical trials.
It is five years this month since a ground-breaking change in UK healthcare history happened – with doctors being able to prescribe cannabis-based medicines for the first time.
An exciting new instrument that will help identify promising drug targets for academia and the pharma industry has been unveiled in Australia by The Monash Institute of Pharmaceutical Sciences (MIPS).
Vice president and global head of bioanalytical and central lab services, Lan Li has always found doctors fascinating. Their ability to save lives and give second chances set her on her career path, but it was recognizing there were still so many unmet...
Unfortunately, more than 700 rare diseases affect more than 30 million people in the US alone and with many of them being life threatening, it is still a concern that most still do not have treatments.
By By Michael Braunagel, managing director, Actigen
Enzyme replacement therapy (ERT) made its debut in 1991, heralding a breakthrough in medical science for individuals and families grappling with rare diseases stemming from single gene mutations.
Integrated drug discovery contract research organization (CRO) Sygnature Discovery has invested £3.75 million in an Azenta compound management storage system that can also provide customer libraries.
The Gen AI revolution promises to redefine various industries, with the life sciences sector at the forefront of this transformation. OSP had the chance to speak to Tarun Mathur, CEO at Indegene, who was keen to allay many of the fears those in the industry...
A new generative artificial intelligence (AI) tool has been launched by H1, a global healthcare data company and will have a 'profound impact on clinical trial diversity'.
Contract research organization (CRO), Phastar, has had its net-zero target approved by SBTi which it hopes to achieve by adopting stringent sustainability standards.
At DPharm 2023, there was a huge meeting of minds to discuss the latest innovations in clinical trials. Outsourcing Pharma was delighted to have an in-depth discussion with IQVIA’s Elan Josielewski, senior principal and head of operations, patient centered...
The U.K. startup Automata Technologies has bagged $40 million in a funding round to expand its workforce and the geographic reach of its life sciences lab automation technology.
A new approach to discovering targets for Alzheimer’s and other neurodegenerative diseases has been presented by Insilico Medicine with the University of Cambridge, UK.
The French-U.S. company Novadiscovery has hailed a “watershed moment for clinical trial design” as its trial simulation tool successfully predicted the outcome of a phase 3 oncology trial run by AstraZeneca.
The U.S. company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.
The AstraZeneca-owned company Alexion has teamed up with Verge Genomics to deploy the U.S. startup’s drug discovery platform in the search for novel drug targets for rare neurodegenerative and neuromuscular diseases.
An oral treatment, developed by the U.S. company Crinetics Pharmaceuticals, Inc., has shown promise as an alternative to injected therapies for tackling the rare disease acromegaly in a phase 3 trial.
HumanFirst, a cloud-based software company accelerating patient-centered drug development through AI, has announced the launch of its precision measures platform.
Glasgow diagnostics spinout Microplate Dx has closed a £2.5 million seed funding round to develop its point-of-care diagnostic platform, which can confirm the presence of bacteria and rapidly identify effective antibiotics to use and which ones to avoid....
The UK startup Intelligent OMICS (Intellomx) has launched a collaboration with Johnson & Johnson’s pharmaceutical company Janssen to use artificial intelligence (AI) to discover drug targets for the treatment of blood cancer.
Less than a month after the U.S. Food and Drug Administration (FDA) gave its antidepressant drug zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its drug development efforts and laying...
The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.
More people are talking about mental illness than ever before. However, despite increased awareness, it remains one of the most neglected areas of public health globally, with research and quality of care lagging behind physical health conditions.
A kidney disease drug with a ‘durable and clinically meaningful impact on kidney function’ has been granted priority review by the US Food and Drug Administration (FDA).
The first oral pill in the United States specifically for postpartum depression, a serious mental illness, has been approved by the US Food and Drug Administration (FDA).
Dr. Susan Wood is CEO and president of VIDA Diagnostics. She has over 25 years of experience championing clinical intelligence solutions into routine clinical use.
The EMA organized a task force made up of various stakeholders to gather insights on potential EU-level actions to improve the set up of clinical trials during public health emergencies.
Phesi, a global provider of patient-centric data analytics, has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date.
Greenphire, provider of clinical trial financial solutions, has released its global 2023 State of Clinical Trial Patient Convenience Market Trends survey.